Roy S. Herbst, MD, PhD, Ensign Professor of Drugs (Medical Oncology), professor, pharmacology, deputy director, Yale Most cancers Middle; chief, Medical Oncology, director, Middle for Thoracic Cancers, Yale Most cancers Middle and Smilow Most cancers Hospital; assistant dean, Translational Analysis, Yale Faculty of Drugs, discusses the significance of consulting a multidisciplinary tumor board when making therapy selections for sufferers with non–small cell lung most cancers (NSCLC), in addition to the optimum therapy course for sufferers with stage III, EGFR-mutated illness.
